ClinicalTrials.gg
RecruitingNCT04984668Updated Feb 9, 2024

A Phase Ib/II Study of GT90001 Combined With KN046 in Solid Tumors

A Phase 1/2 interventional study of GT90001+KN046 and GT90001+KN046 in Solid Tumor, sponsored by Suzhou Kintor Pharmaceutical Inc,. Recruiting at 1 site in Taiwan. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-02-09.

Sponsored by Suzhou Kintor Pharmaceutical Inc, · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Apr 2025, 1 year 7 months ago, but the record still lists the study as recruiting.
  • Started Nov 2021; still recruiting 5 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
216
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

Phase Ib is a dose De-escalation study to evaluate the safety, tolerability, pharmacokinetics (PK) and preliminary antitumor activity of GT90001 in combination with KN046 in subjects with advanced or refractory hepatocellular carcinoma (HCC), gastric carcinoma (GC) and gastroesophageal junction (GEJ) adenocarcinoma, urothelial carcinoma (UC) and esophageal square cell carcinoma (ESCC).

Phase II is to investigate anti-tumor efficacy of GT90001 in combination with KN046 at RP2D in subjects with specific types of tumors. A Simon two-stage design is planned for each indication in order to minimize the number of treated participants if there is minimal efficacy activity in that indication.

02

Conditions studied

  • Solid Tumor
03

In context

Lead sponsor

Suzhou Kintor Pharmaceutical Inc, is the lead sponsor of 18 studies on the registry; 2 are open to participants now.

Of its 7 completed or terminated interventional studies of FDA-regulated products, 2 (29%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

General

  1. Age ≥18 years, or ≥ minimum legal age to attend a clinical study.
  2. Be willing and able to provide written /assent for the trial.
  3. Ability to comply with requirements of the protocol, as assessed by the investigator.
  4. Disease-Specific Inclusion Criteria All subjects must have unresectable locally advanced or tumors that have histologic or cytological documentation confirmed.

    • Phase Ib: subjects with advanced HCC, GC or GEJ adenocarcinoma, Urothelial transitional cell Carcinoma and Esophagus Carcinoma who have progressed despite standard therapies, are intolerant of standard therapy, or for whom no standard therapy exists;
    • Phase II: subjects with tumor of specific types:

Cohort# Indication Inclusion criteria

  1. HCC, 2L Unresectable histologic confirmed primary hepatocellular carcinoma. Subjects with radiological diagnosis may also be enrolled in the study.

    Documented radiographic or clinical disease progression during or after therapy, including Sorafenib, Lenvatinib and Atezolizumab plus Bevacizumab and other 1st line standard care per local clinical practice.

    Patient has a score of 5 or 6 points and no encephalopathy and/or clinically apparent ascites. (Note: Child-Pugh score should be evaluated within 7 days of first dose of study drug)

  2. GC or GEJ adenocarcinoma, 3L Unresectable locally advanced or metastatic GC or GEJ carcinoma and have confirmed adenocarcinoma.

    At least 50% subjects with expression (CPS) on ≥ 1% will be enrolled in this cohort.

    Has experienced documented objective radiographic or clinical disease progression during or after standard first line Platinum- and fluoropyrimidine-based two or three cytotoxic drug chemotherapy and second line NCCN recommended treatment regimen therapy or other 1st and 2nd line standard care per local clinical practice. (Note: subjects with discontinuation due to AEs prior to disease progression are not considered as treatment failure unless disease progression is confirmed by documentation.) Disease progression during or within 6 months following the last dose of or neo-adjuvant therapy will be considered as 1st line failure.

  3. UC, 2L Histologically or cytologically confirmed urothelial carcinoma of the renal pelvis, ureter, bladder, or urethra that showed predominantly transitional-cell features Has experienced documented progression or recurrence after at least the 1st line platinum-based chemotherapy or recurrence within 12 months after the receipt of platinum-based adjuvant or neoadjuvant therapy for localized muscle-invasive disease.

Note: Primary chemoradiation for unresectable muscle-invasive bladder cancer with the aim of bladder preservation will not be considered a prior line of systemic therapy for the purposes of determining study eligibility.

4 ESCC 2L Histologically confirmed, unresectable squamous cell carcinoma of the esophagus.

The primary tumor must originate in the esophagus. Tumors that involve the GE junction must meet Sievert Type 1 criteria, 1-5 cm above the EGJ. For the purposes of this protocol, this will be interpreted as: greater than 50% of the tumor must be above the GE junction.

Patients must have received at least one prior therapy for unresectable disease. Patients with recurrence within 6 months of completion of neoadjuvant or adjuvant therapy may be considered as having received one prior therapy for unresectable disease.

  1. Patient must have at least one by CT or MRI per 1.1. Tumor lesions situated in a previously irradiated area are considered measurable if progression has been demonstrated in such lesions. Loco-regional treated lesion cannot be selected as a target lesion.
  1. performance status score of 0 or 1. 7. ≥ 12 weeks. 8. At screening, patients in Phase II part must agree to provide , if available, for biomarker testing. When archival tissue is not available, it is optional for patients to undergo fresh biopsy judged medically safe by the investigator.
  1. Archival tumor tissue can be formalin-fixed paraffin embedded (FFPE) tissue block (preferably collected within 12 months before the first dose) or at least 5 freshly sectioned unstained slides. Tissue block is preferred over unstained slides.
  2. Acceptable tissue sample include core needle punctured, resected or incisional biopsy, or surgical sample. (Note: Fine needle aspirational cytology (FNAC) sample is not acceptable. Tumor tissue from bone metastases is not evaluable for determination of PD-L1 expression and is therefore also not acceptable.) 9. Any toxic effects of prior anti-cancer therapy or surgical procedures resolved to baseline severity or version 5 Grade ≤ 1 (except alopecia or other toxicities not considered a safety risk for the patient at investigator's discretion).

Clinical Laboratory Inclusion Criteria

  1. Subject must have adequate organ function as indicated by the following laboratory values [had not received blood transfusion, erythropoietin (EPO), granulocyte colony stimulating factor (G-CSF) or other relevant medical support within 14 days before the administration of the product]:

(ANC) ≥ 1.5×109/L ≥ 100 ×109/L (≥ 60 ×109/L for HCC subjects) ≥ 9 g/dL or ≥ 5.6 mmol/L Serum creatinine ≤ 1.5 × (ULN); AND calculated (CrCL) > 50 mL/min (Cockcroft-Gault formula) Total ≤ 1.5 × ULN OR ≤2.5 × ULN for HCC OR ≤ 2 × ULN in case of known Gilbert disease (SGOT) and ALT (SGPT) ≤ 2.5 × ULN OR ≤ 5 × ULN for HCC patients or patients with liver metastases Serum albumin ≥ 28 g/L (no albumin transfusion within 14 days) (INR) or Prothrombin Time (PT) ≤ 1.5 × ULN Activated Partial Thromboplastin Time (aPTT) ≤ 1.5 × ULN

  1. Subjects with virus (HBV) infection must have HBV DNA \< 2000 IU/mL at screening.

Subjects with positive HBsAg and/or positive HBV DNA that requires anti-HBV treatment for at least 2 weeks prior to the first dose of study drugs and are willing to continue receiving antiviral treatment.

  1. Women of (WOCBP) must have a negative pregnancy test result. Either Female or male patients must agree to use adequate measures from signing informed consent and for 180 days after last investigational product administration, except for a patient with documented surgical sterilization or a female.

Exclusion criteria

Exclusion criteria:

Target Disease Exceptions 1. For phase II expansion study, patients with specific types of tumors are also required to be excluded by following criteria: Cohort # Indication Exclusion criteria

  1. HCC, 2L Fibrolamellar, sarcomatoid and mixed hepatocellular/ cholangiocarcinoma histology Any history of hepatic encephalopathy Active coinfection with both and C, as evidenced by positivity of both HBV DNA and .
  2. GC or GEJ adenocarcinoma, 3L Has squamous cell, undifferentiated, mixed or other histology other than gastric adenocarcinoma.
  3. UC, 2L Has locally advanced UC is suitable for local therapy administration with curative intention (as determined by local investigators)
  4. ESCC 2L Has locally advanced esophageal carcinoma that is resectable or potentially curable with radiation therapy (as determined by local investigator) confirmed, unresectable adenocarcinoma, undifferentiated carcinomas or adenosquamous carcinomas of the esophagus.

Tumors that involve the GE junction Sievert Type 2 and Sievert Type 3, or greater than 50% of the tumor below the GE junction as determined by endoscopy.

Medical History and Concurrent Diseases

  1. Prior active within the previous 3 years except for locally curable cancers that have been apparently cured, such as basal or squamous cell skin cancer, superficial bladder cancer, or carcinoma in situ of the prostate, cervix, or breast.
  1. Has known active central nervous system (CNS) and/or carcinomatous meningitis. Patients with previously treated may participate provided they are stable (without evidence of progression by imaging for at least 4 weeks prior to the first dose of product and any neurologic symptoms have returned to baseline), have no evidence of new or enlarging brain metastases, and are not using for at least 7 days prior to study treatment.
  2. Any prior (within 1 year) or current ascites as measured by physical examination and that requires active paracentesis for control.
  3. Patients with active, known, or suspected disease. Patients with Type I diabetes mellitus, residual hypothyroidism due to autoimmune thyroiditis only requiring hormone replacement, or skin disorders (such as vitiligo, psoriasis, or alopecia) not requiring systemic treatment are permitted to enroll. For any cases of uncertainty, it is recommended to discuss with sponsor prior to signing .
  4. Significant history of cardiac disease (i.e., unstable angina, congestive heart failure, as defined by the [NYHA] as Class II, III, or IV) within 6 months prior to Day 1 of Cycle 1, myocardial infarction within the previous year, or current cardiac ventricular arrhythmias requiring medication., or (LVEF) is below 50%.
  5. Arterial or venous thrombotic or embolic events such as cerebrovascular accident (including ), deep vein thrombosis or pulmonary embolism within 6 months before the start of study treatment.
  6. Any hemorrhage or bleeding event≥ Grade 3 within 28 days prior to the start of study treatment.
  7. Has a history of (non-infectious) pneumonitis that required steroids or current pneumonitis.
  8. Patients with active tuberculosis or history of tuberculosis.
  9. Any serious or uncontrolled medical disorder or active infection that, in the opinion of the investigator, may increase the risk associated with study participation, study drug administration, or would impair the ability of the patient to receive study drug.
  10. Patients with any active infections requiring systemic therapy within 2 weeks prior to the initiation of the study treatment.
  11. Known history of positive test for (HIV) or known acquired immunodeficiency syndrome (AIDS).
  12. Subjects who are hepatitis C virus (HCV) antibody positive at screening, must not be enrolled until further definite testing with HCV RNA tests can conclusively rule out the presence of active infection (HCV RNA exceeding the lower detection limit) requiring antiviral therapy for Hepatitis C.
  13. History of organ transplantation requiring the use of treatment.

    Prior treatments

    1. Patients who have received systemic anti-tumor treatments 21 days prior to the initiation of the study treatment, including chemotherapy, immunotherapy, biological therapy (tumor vaccine, cytokines, or growth factors controlling the progression of cancers).
    1. Patients who received radiotherapy within 4 weeks prior to start of study drug. Palliative radiotherapy for symptomatic control is acceptable (if completed at least 2 weeks prior to study drug administration) and no additional radiotherapy for the same lesion is planned.
    1. Major surgical procedure, open , or significant traumatic injury within 28 days prior to initiation of study treatment, or anticipation of need for major surgical procedure during the course of the study.
    1. Has had a minor surgery (i.e. simple excision, tooth extraction) ≤ 7 days prior to the first dose of study treatment is permitted; 7. Patients who have received treatment with NMPA approved anti-tumor Chinese herbal medicine or Chinese prepared medicine within 14 days prior to the initiation of the study treatment.
    1. Has received locoregional therapy to liver (transchetheter chemoembolization (TACE), transchetheter embolization (TAE), hepatic arterial infusion(HAI), radiation, radioemboliztion or ablation) within 4 weeks of start of study treatment. Has received Y90-selective internal radiation therapy (SIRT) within 90 days or 5 half-lives (whichever is longer) prior to the first dosing.
    1. Patients with a condition requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalents) or other immunosuppressive medications within 14 days of study drug administration. Inhaled or topical steroids, and adrenal replacement doses ≤ 10 mg daily prednisone equivalents are permitted in the absence of active autoimmune disease. A brief course of corticosteroids for the prophylaxis (e.g., contrast dye allergy) or treatment of non-autoimmune conditions (e.g., delayed-type reaction caused by contact allergen) is permitted.
    1. Subjects with history of life-threatening toxicity related to prior immune therapy (e.g., /PD-L1 treatment) except those that are unlikely to re-occur with standard countermeasures (e.g., Hormone replacement after adrenal crisis); 11. Only patients in Phase II (except cohort 1, HCC): Prior treatment with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CTLA-4, anti-CD137, anti-TIM-3, anti-LAG-3 antibody, or any other antibody or drug specifically targeting T-cell co stimulation or checkpoint pathways.
    1. Administration of a live or attenuated vaccine within 28 days prior to initiation of study treatments.

    Allergies and Adverse Drug Reaction 13. History of allergy or hypersensitivity, or any to study drug components.

    Other Exclusion Criteria

    1. Patients with a known history of alcoholism or drug abuse. 15. Female patients who are pregnant or breast-feeding. 16. Patients with a history of mental illness, or who are incapacitated or have limited capacity.
    1. Other conditions that, in the investigators' opinion, would make patients inappropriate to participate in this study.
    1. Patients who are anticipating in other clinical studies or the planned first dose of study treatment is less than 4 weeks after the last dose of treatment in previous clinical study.
Terms in these criteria, in plain language(39)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
216 participants (estimated)

Study arms

  • Experimental
    GT90001+KN046

    GT90001, 100 mg/10 mL/vial. GT90001 will be administered via intravenous infusion (IV) for around 60 minutes, once every 2 weeks (Q2W) in each 14-day cycle. KN046, 40 mg/1.6 mL/vial, 300 mg/12 mL/vial KN046 will be administered via intravenous infusion (IV) for at least 120 minutes (up to 4h for the first 6 cycles), once every 2 weeks (Q2W) in each 14-day cycle, after 60 minutes post the GT90001 taken.

    Drug: GT90001+KN046 · Drug: GT90001/KN046

Interventions

06

What researchers measure

Primary outcomes

  1. Treatment-emergent adverse events (TEAEs), treatment-related AEs (TRAEs), serious adverse events (SAEs), Dose Limiting Toxicities (DLTs)

    safety

    Time frame: until progression or death,whichever came first, assessed up to 2 years

  2. Phase 2 dose (RP2D) of GT90001 in combination with KN046

    RP2D

    Time frame: after completion of the DLT evaluation of the last subject of Phase Ib, up to 28 days

  3. Objective response rate

    Efficacy

    Time frame: until progression or death,whichever came first, assessed up to 2 years

Secondary outcomes

  1. ORR (Phase Ib) in %, disease control rate (DCR) in %, progression-free survival (PFS)in months, and duration of response (DoR) in %

    Efficacy

    Time frame: until progression or death,whichever came first, assessed up to 2 years

  2. AUC0-t, Cmax, Tmax, t½ , CLss for GT90001 , Ctroug for KN046 (only Phase Ib)

    Pharmacokinetic evaluations

    Time frame: until progression or death,whichever came first, assessed up to 2 years

  3. occurrence of anti-GT90001 and anti-KN046 antibody

    immunogenecity

    Time frame: until progression or death,whichever came first, assessed up to 2 years

  4. TEAEs, severity of TEAEs, TRAEs, SAEs

    safety

    Time frame: until progression or death,whichever came first, assessed up to 2 years

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Nov 2021 (actual). Primary completion is estimated for Apr 2025, 41 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 5, 2021
First posted
Jul 30, 2021
StartActual
Nov 2, 2021
Primary completionEst.
Apr 2025
CompletionEst.
Dec 2025
Last update
Feb 9, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 9, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04984668
Lead sponsor
Suzhou Kintor Pharmaceutical Inc,
Responsible party
Sponsor
First posted
Jul 30, 2021
Start date
Nov 2, 2021
Primary completion
Apr 2025 (estimated)
Completion
Dec 2025 (estimated)
Last update
Feb 9, 2024

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Ascrinvacumab · Erfonrilimab

Start the discussion